4.0
Feb 27, 2013
Recommend
CEO approval
Business Outlook
Pros
I like the company feeling and that it's not too extravagant compared to other pharma.
Cons
Bad luck with the oncology pipeline, a little depressing at the moment. Darmstadt really sucks unfortunately.